Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought

But elephant in the room –  the coming stream of readouts from Phase III PIONEER trials on oral semaglutide  in Type 2 diabetes – gets little mention at first-quarter update.

Diabetes
Effective launch of the once-weekly GLP-1 Ozempic is vital for the future of Novo Nordisk • Source: Shutterstock

More from Strategy

More from Business